Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%

Event‐free survival · people with systemic sclerosis

Autologous myeloablative selective HSCT showed no clear difference in event‐free survival compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
HR 0.54 [0.23, 1.27]
1 study · 75 participants
Moderate

Event‐free survival · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to lower event‐free survival compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
HR 0.34 [0.16, 0.74]
1 study · 156 participants
Moderate

Event‐free survival · people with systemic sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found